Highlights:
- Pioneering Precision: "Follow Your Heart" Integrates Health Gauge's Revolutionary EdgeAI and AI PrecisionPulse Neural Network Measurement Technology to produce a consumer wellness smartwatch solution with medical grade accuracy for blood pressure measurements.
VICTORIA, BC / ACCESSWIRE / March 6, 2024 / AI/ML Innovations Inc. (the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a leading company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is pleased to have received the following from its majority-owned subsidiary, Health Gauge Inc.:
Health Gauge Inc., a leading name in health tech innovation, proudly announces the commercial launch of "Follow Your Heart," a unique wellness-oriented product set to redefine how individuals monitor their blood pressure trends through the convenience of a smart watch. Combining cutting-edge technology with user-friendly design, "Follow Your Heart" leverages Health Gauge's proprietary and patented AI PrecisionPulse Neural Network measurement technology. The result is a non-invasive solution that is able to provide medical grade accuracy for blood pressure measurements and trends, through the convenience of a smartwatch. The product will be available for purchase through retail pharmacies and other channels catering to individuals managing hypertension.
According to recent statistics, nearly one half of adults in the U.S. suffer from high blood pressure, underscoring the critical need for reliable and accessible blood pressure monitoring solutions. "Follow Your Heart" emerges as a timely response to this health challenge, empowering users to take control of their cardiovascular well-being with ease.
Addressing the Hypertension Epidemic in the United States[1]
- Having hypertension puts you at risk for heart disease and stroke, which are leading causes of death in the United States.
- In 2021, hypertension was a primary or contributing cause of 691,095 deaths in the United States.
- Nearly half of adults have hypertension (48.1%, 119.9 million), defined as a systolic blood pressure greater than 130 mmHg or a diastolic blood pressure greater than 80 mmHg or are taking medication for hypertension.
- About 1 in 4 adults with hypertension have their hypertension under control (22.5%, 27.0 million).
- About half of adults (45%) with uncontrolled hypertension have a blood pressure of 140/90 mmHg or higher. This includes 37 million U.S. adults.
- About 34 million adults who are recommended to take medication may need it to be prescribed and to start taking it. Almost two out of three of this group (19 million) have a blood pressure of 140/90 mmHg or higher.
- High blood pressure costs the United States about $131 billion each year, averaged over 12 years from 2003 to 2014.
Paul Duffy, CEO of AI/ML Innovations Inc., added "We are thrilled to introduce 'Follow Your Heart,' a product that epitomizes our commitment to leveraging cutting-edge technology for the betterment of human health. In an era where health consciousness is paramount, 'Follow Your Heart' provides a user-friendly and non-invasive solution for individuals seeking precision in blood pressure trend monitoring. "Follow Your Heart" will help democratize your health and wellness by providing you, the wearer, with immediate and actionable feedback regarding your blood pressure. At AI/ML Innovations Inc., we believe in pioneering innovations that make a tangible impact on people's lives. 'Follow Your Heart' is a testament to that ethos."
###
[1]
About Health Gauge
Users can explore the features and benefits of "Follow Your Heart" by visiting the dedicated webpage:
Health Gauge, a majority-owned subsidiary of AI/ML Innovations Inc., is at the forefront of revolutionizing healthcare through the power of Health Intelligence. With a commitment to leveraging technology for human well-being, Health Gauge provides cutting-edge solutions for personalized health insights.
About AI/ML Innovations Inc.
AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge (95.2% owned by AIML), Tech2Heal (up to 22% ownership rights, with 12.44% currently owned by AIML), AI Rx Inc. (70% owned by AIML) and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AI/ML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".
On behalf of the Board of Directors
Tim Daniels, Executive Chairman
For more information about AI/ML Innovations:
For detailed information please see AI/ML's website or the Company's filed documents at
For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
For AI/ML Innovations Investors
Certain statements made in this press release that are not based on historical information are forward-looking statements that involve substantial known and unknown risks and uncertainties. This press release contains express or implied forward-looking statements relating to, among other things, AI/ML Innovations' expectations concerning management's plans, objectives, and strategies, including strategies for defending the Company's intellectual property. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. AI/ML Innovations Inc. undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events, or circumstances or otherwise except as expressly required by applicable securities law. Further information regarding the uncertainties and risks can be found in the disclosure documents filed by AI/ML with the securities regulatory authorities, available at .
SOURCE: AI/ML Innovations Inc.
亮点:
- 开创精度:“Follow Your Heart” 整合了Health Gauge的革命性EdgeAI和AI PrecisionPulse神经网络测量技术,生产出具有医疗级血压测量精度的消费类健康智能手表解决方案。
不列颠哥伦比亚省维多利亚州/ACCESSWIRE/2024年3月6日/ AI/ML Innovations Inc.(“公司”)(CSE: AIML)(OTCQB: AIMLF)(FWB: 42FB)是一家致力于收购和推进满足紧急社会需求的人工智能/机器学习技术的领先公司,很高兴从其控股子公司Health Gauge Inc.获得以下信息:
健康科技创新领域的领军企业Health Gauge Inc. 自豪地宣布商业推出 “Follow Your Heart”,这是一款以健康为导向的独特产品,旨在通过智能手表的便利性重新定义个人监测血压趋势的方式。“Follow Your Heart” 将尖端技术与人性化设计相结合,利用了Health Gauge的专有专利AI PrecisionPulse神经网络测量技术结果是一种非侵入性的解决方案,能够通过智能手表的便利性为血压测量和趋势提供医疗级的准确性。该产品将可通过零售药房和其他面向高血压患者的渠道购买。
根据最近的统计数据,美国将近一半的成年人患有高血压,这突显了对可靠和易用的血压监测解决方案的迫切需求。“Follow Your Heart” 是对这一健康挑战的及时回应,使用户能够轻松控制自己的心血管健康。
应对美国的高血压疫情 [1]
- 患有高血压会使你面临心脏病和中风的风险,而心脏病和中风是美国的主要死亡原因。
- 2021年,高血压是美国691,095人死亡的主要或促成原因。
- 将近一半的成年人患有高血压(48.1%,1.199亿),其定义是收缩压大于130 mmHg或舒张压大于80 mmHg或正在服用高血压药物。
- 大约四分之一的高血压成年人的高血压得到控制(22.5%,2700万)。
- 在患有未控制的高血压的成年人中,约有一半(45%)的血压为140/90 mmHg或更高。这包括3700万美国成年人。
- 大约有3,400万被推荐服药的成年人可能需要开处方才能开始服药。该群体中几乎有三分之二(1900万)的血压为140/90 mmHg或更高。
- 高血压每年给美国造成约1310亿美元的损失,在2003年至2014年的12年中平均损失了约1310亿美元。
AI/ML Innovations Inc.首席执行官保罗·达菲补充说:“我们很高兴推出'Follow Your Heart ',该产品体现了我们致力于利用尖端技术改善人类健康的承诺。在健康意识至高无上的时代,“Follow Your Heart” 为寻求精确血压趋势监测的个人提供了一种用户友好且非侵入性的解决方案。“Follow Your Heart” 将通过为佩戴者提供有关血压的即时且切实可行的反馈,帮助您的健康和保健大众化。在AI/ML Innovations Inc.,我们相信开创性的创新会对人们的生活产生切实的影响。'Follow Your Heart'证明了这种精神。”
###
[1]
关于生命值计
用户可以通过访问专用网页来探索 “Follow Your Heart” 的特点和好处:
Health Gauge是AI/ML Innovations Inc.的多数股权子公司,站在通过健康情报的力量彻底改变医疗保健的最前沿。Health Gauge致力于利用技术促进人类福祉,为个性化健康见解提供尖端解决方案。
关于 AI/ML Innovations Inc.
AI/ML Innovations Inc.调整了其业务运营,以利用新兴的人工智能(AI)和机器学习(ML)领域,最初的投资重点是新兴的数字健康和福祉公司,这些公司利用人工智能、机器学习、云计算和数字平台推动变革性的医疗管理解决方案和整个健康连续体的精准支持交付。通过与Health Gauge(AIML持有95.2%的股权)、Tech2Heal(高达22%的所有权,目前由AIML持有12.44%的所有权)、AI Rx Inc.(AIML持有70%的股权)以及其他计划中的增值投资,公司继续利用不断扩大的增长领域,使公司所有利益相关者受益。AI/ML的股票在加拿大证券交易所交易,代码为 “AIML”,OTCQB风险投资市场以 “AIMLF” 的形式交易,在法兰克福证券交易所交易的代码为 “42FB”。
代表董事会
蒂姆·丹尼尔斯,执行主席
有关 AI/ML 创新的更多信息:
有关详细信息,请访问AI/ML的网站或公司提交的文件,网址为
欲了解更多信息,请致电 (778) 405-0882 或 info@aiml-innovations.com 与 Blake Fallis 联系
CSE及其监管服务提供商(该术语在CSE的政策中定义)均不对本新闻稿的充分性或准确性承担责任。
致人工智能/机器学习创新投资者
本新闻稿中发表的某些非基于历史信息的陈述是前瞻性陈述,涉及大量已知和未知的风险和不确定性。本新闻稿包含与AI/ML Innovations对管理层计划、目标和战略(包括捍卫公司知识产权的战略)的预期有关的明示或暗示的前瞻性陈述。这些陈述既不是承诺也不是担保,但存在各种风险和不确定性,其中许多风险和不确定性是我们无法控制的,这可能导致实际结果与这些前瞻性陈述中设想的结果存在重大差异。提醒现有和潜在投资者不要过分依赖这些前瞻性陈述,这些陈述仅代表截至本文发布之日。除非适用的证券法明确要求,否则AI/ML Innovations Inc. 没有义务更新或修改本新闻稿中包含的信息,无论是由于新信息、未来事件或情况还是其他原因。有关不确定性和风险的更多信息,可以在AI/ML向证券监管机构提交的披露文件中找到,网址为。
来源:AI/ML Innovations Inc.